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Introduction
The International Society of Nephrology sponsored a benefit ratio, and some luck led to a cure of a very severe
Forefronts in Nephrology Symposium on the topic of disease. Perhaps the best lesson from these three SCID-
“Gene Therapy and Renal Disease,” which was held in X1 patients is the recognition of the enormity of the
Beavercreek, Colorado on June 4–6, 2000. This exciting basic science effort required to provide the foundation
conference was a satellite symposium to the American for a clinical success.
Society of Gene Therapy’s (ASGT) National Meeting The Jesse Gelsinger case is tragic but also provides ad-
in Denver, Colorado, and the meeting was co-chaired by ditional insights. OTC is a rare disease of ammonia me-
the President of the ASGT, Savio Woo, and Paul Klotman. tabolism. The total absence of the enzyme causes death
The landscape for gene therapy has changed dramati- from ammonia intoxication shortly after birth. In pa-
cally. There has been one success in gene therapy: Alain tients who are not totally defective but have some en-
Fischer’s group has successfully treated three children zyme activity, ammonia levels can be controlled by diet
with combined immune deficiency. There also has been and drugs. It is an appropriate target for gene therapy
one prominent death in the treatment of ornithine trans- in that replacement in deficient individuals should, in
carbamylase deficiency (OTC). Both are important il- theory, be curative. The death of the patient in this dose
lustrations of the success and failure of gene therapy. escalation phase 1 trial is a reminder of the dangers in-
Fischer’s group managed to cure a very rare but severe herent in novel therapeutic approaches. Although the
disease known as SCID-X1, which is an X-linked disor- exact cause of death remains unclear, a large antigen
der due to mutations in the c subunits of the interleukin load is likely to have played a role. The molecular target
(IL)-2, -4, -7, -9, and -15 cytokine receptors that are re- OCT, like the c cytokine subunit in the SCID-X1 suc-
quired for lymphoid differentiation (Cavazzana-Calvo cess, was clearly established. Some questions include:
et al, Science 288:669–672, 2000). These children manifest was adenovirus the correct vector, was the route of ad-
the classic “bubble kid” syndrome with severe combined ministration the correct one, was the severity of the dis-
immune deficiency, susceptibility to infection that re- ease great enough, and was the risk-benefit ratio appro-
quires reverse isolation, and failure to thrive. As the first priate? These are all very difficult issues that must be
true success of gene therapy, it is quite illustrative to addressed with each application of molecular based ther-
explore why this was a positive intervention. First, the apy. In addition, this case reinforces the notion that while
molecular target was clearly defined and the risk-benefit gene therapy ultimately may be applied for the treatment
ratio clearly warranted aggressive intervention. In addi- of hypertension and diabetes, the early applications are
tion, there was a great deal of preclinical work in vitro more likely to focus on much higher risk but rare diseases
and in animals that suggested this strategy would be suc- for which no other forms of therapy are available.
cessful. The basic strategy for ex vivo transduction and It is probable that rare diseases of inheritance or se-
expansion of cells ex vivo had been established. How- vere uncurable diseases, like certain cancers or infectious
ever, additional significant advances were made in the diseases or HIV-1, will remain the molecular targets in the
ability to identify hematopoietic precursors (CD 34 near future. There is considerable optimism that hemo-
stem cells) and to expand them ex vivo with cytokine philia A and B will be approachable. This is a particularly
growth factors, which allowed the target cell to be acces- attractive disease to treat since factor IX production may
sible ex vivo. Finally, an appropriate and safe vector was occur in any convenient cellular reservoir and low levels
used to transduce these cells. One additional key factor may be sufficient to reverse the disease. There also has
that probably contributed to the success whereas adeno- been a renewed interest in gene therapy approaches for
sine deaminase (ADA) deficiency has met with so many HIV-1 because of the need for resistant cells for immune
obstacles; the presence of the reconstituted receptor pro- reconstitution in patients whose viral burden is con-
vided a growth advantage in vivo for transduced cells. trolled. For the near term, rare inherited diseases will
Thus, understanding the molecular target, knowledge of
likely remain the nearest successful targets for molecular
pathogenesis, advances in stem cell biology, the choice
based therapy.of the correct vector in the right cells, the correct risk-
In this regard, dramatic advances have been made in
the identification of Mendelian disorders that affect the
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meostasis, and glomerular function. These are generally cellular mechanisms are responsible for disease before
rare diseases but the molecular targets are clear. Because a successful cure will be achieved. Thus, the issues related
several lead to death, such as pseudohypoaldosteronism to gene replacement remain exceedingly complex.
type I, they will be candidates for molecular therapy. It The purposes of this Forefronts Symposium included
is necessary to understand the molecular mechanisms of an exploration of what is known about molecular thera-
disease because the replacement of a defective gene may peutic approaches, what appear to be the current state-
not be straightforward. Cystic fibrosis is a perfect exam- of-the-art delivery systems (both viral and nonviral), ap-
ple in which the genetic defect was identified, the CFTR propriate disease targets, how stem cells can be used for
gene was cloned, and vectors created to replace the gene therapy, what renal disease models can be utilized, and
were generated. Yet, simply transducing respiratory epi- what diseases in humans are most approachable.
thelial cells does not provide a cure. Much more remains
to be understood about pathogenesis, about how the Savio Woo and Paul Klotman
Guest Editorspolarized epithelium processes the channel, and which
